Marvel Biosciences Corp. MBCOF의 지난 분기 매출 실적은 어땠나요?
Marvel Biosciences Corp.의 매출 추정치는 얼마인가요?
Marvel Biosciences Corp.의 수익 품질 점수는 얼마인가요?
Marvel Biosciences Corp.는 언제 수익을 보고하나요?
Marvel Biosciences Corp.의 예상 수익은 얼마인가요?
Marvel Biosciences Corp.은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$0.0938
시가
$0.0938
일일 범위
$0.0938 - $0.0938
52주 범위
$0.046 - $0.241
거래량
1.0K
평균 거래량
10.4K
EPS(TTM)
-0.04
배당수익률
--
시가총액
$5.4M
MARVEL BIOSCIENCES CORP.란 무엇인가요?
Marvel Biosciences Corp. is a biotechnology company that utilizes a drug redevelopment approach to drug development. The company is headquartered in Calgary, Alberta. The company went IPO on 2019-02-28. The firm develops new synthetic chemical derivatives of the original approved drug for the new disease indication. The company has developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs that inhibit the A2a adenosine receptor with application to neurological diseases (depression and anxiety, Alzheimer's, attention deficit hyperactivity disorder (ADHD)), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. The firm's lead compound, MB-204, is a fluorinated derivative of Istradefylline. The firm is engaged in developing MB-204 for diseases other than Parkinson's disease, specifically depression, Alzheimer’s Disease and liver fibrosis due to non-alcoholic steatohepatitis (NASH). Its wholly owned subsidiary is Marvel Biotechnology Inc.